奧戈伏單抗(INN:Oregovomab;商品名OvaRex銷售)是一種小鼠單株抗體,它與抗原CA125(一種碳水化合物抗原)結合。它被設計用於治療卵巢癌。[1][2]
該藥物由AltaRex公司開發。[3]
參考資料
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Oregovomab (頁面存檔備份,存於網際網路檔案館), American Medical Association.
- ^ Pietragalla, Antonella; Duranti, Simona; Daniele, Gennaro; Nero, Camilla; Ciccarone, Francesca; Lorusso, Domenica; Fagotti, Anna; Scambia, Giovanni. Oregovomab: an investigational agent for the treatment of advanced ovarian cancer. Expert Opinion on Investigational Drugs. 2021-02, 30 (2). ISSN 1744-7658. PMID 33423551. doi:10.1080/13543784.2021.1868436.
- ^ Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13. Drugs in R&D. 2006, 7 (6) [2024-03-04]. ISSN 1174-5886. PMID 17073521. doi:10.2165/00126839-200607060-00007. (原始內容存檔於2024-06-04).